financetom
Business
financetom
/
Business
/
Citi says 42% of energy clients lack climate transition plans
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Citi says 42% of energy clients lack climate transition plans
Mar 28, 2024 10:03 AM

NEW YORK, March 28 (Reuters) - Almost half of the energy

companies Citi lends to are lacking plans to cut

greenhouse gas emissions, the fourth-largest U.S. bank said in a

climate report released on Thursday.

Banks are combing through their loan books for information

on the risks businesses face from climate change and how they

are preparing to shift to a lower-carbon economy, as regulators

around the world increase their own demands for disclosure.

Citi ranked the energy companies in its loan portfolio from

"low" to "strong" on the basis of their plans to reduce

emissions across three categories, known as scopes.

In 42% of cases, it found "absence of a substantive

transition plan," and a lack of disclosure of Scope 3 emissions,

which are released into the atmosphere from companies' supply

chains and customers. Those gases usually represent 70% of their

carbon footprints, according to Deloitte consultants.

Citi found just 8% of its energy clients had a

"comprehensive and ambitious transition plan targeting Scopes

1-3 emissions reductions and demonstrated ability to execute."

The proportion rose to 37% when Scope 3 emissions were excluded.

The analysis, started last year, is based on data from 2021.

Chief Sustainability Officer Valerie Smith said she expected the

timing of data collection and analysis to improve.

"We are still in building mode. We understand the

importance of moving forward on climate. We also understand the

energy transition is a monumental effort, it is not happening

overnight," Smith said.

Like many other large banks and companies, Citi has set a

"net zero" target - for business it finances to lead to no more

greenhouse gas emissions than can be absorbed by technology or

natural systems like forests - by 2050.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Cytokinetics Insider Sold Shares Worth $1,099,125, According to a Recent SEC Filing
Cytokinetics Insider Sold Shares Worth $1,099,125, According to a Recent SEC Filing
Jun 7, 2024
04:06 PM EDT, 06/07/2024 (MT Newswires) -- Robert I Blum, Director, President & CEO, on June 04, 2024, sold 22,500 shares in Cytokinetics ( CYTK ) for $1,099,125. Following the Form 4 filing with the SEC, Blum has control over a total of 443,311 shares of the company, with 439,145 shares held directly and 4,166 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1061983/000112760224018143/xslF345X03/form4.xml...
Cava Group Insider Sold Shares Worth $222,512,803, According to a Recent SEC Filing
Cava Group Insider Sold Shares Worth $222,512,803, According to a Recent SEC Filing
Jun 7, 2024
04:07 PM EDT, 06/07/2024 (MT Newswires) -- Ronald M Shaich, Director, on June 05, 2024, sold 2,550,290 shares in Cava Group ( CAVA ) for $222,512,803. Following the Form 4 filing with the SEC, Shaich has control over a total of 7,149,899 shares of the company, with 5,000 shares held directly and 7,144,899 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1639438/000162828024027251/xslF345X03/wk-form4_1717790405.xml Price: 85.00,...
Recursion Pharmaceuticals Insider Sold Shares Worth $871,000, According to a Recent SEC Filing
Recursion Pharmaceuticals Insider Sold Shares Worth $871,000, According to a Recent SEC Filing
Jun 7, 2024
04:07 PM EDT, 06/07/2024 (MT Newswires) -- Christopher Gibson, Director, Chief Executive Officer, on June 05, 2024, sold 100,000 shares in Recursion Pharmaceuticals ( RXRX ) for $871,000. Following the Form 4 filing with the SEC, Gibson has control over a total of 708,738 shares of the company, with 708,738 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000077/xslF345X03/wk-form4_1717790504.xml Price: 8.60, Change: +0.09,...
Blueprint Medicines Insider Sold Shares Worth $420,520, According to a Recent SEC Filing
Blueprint Medicines Insider Sold Shares Worth $420,520, According to a Recent SEC Filing
Jun 7, 2024
04:07 PM EDT, 06/07/2024 (MT Newswires) -- Percy H. Carter, Chief Scientific Officer, on June 05, 2024, sold 4,000 shares in Blueprint Medicines ( BPMC ) for $420,520. Following the Form 4 filing with the SEC, Carter has control over a total of 41,895 shares of the company, with 41,895 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1597264/000141588924015943/xslF345X03/form4-06072024_040602.xml ...
Copyright 2023-2025 - www.financetom.com All Rights Reserved